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Abstract
Background: Breast cancer (BC) is a major public health issue. More than one out of five women treated for breast
cancer will develop lymphedema in an upper extremity. Current evidence advocates transdisciplinary oncological
rehabilitation. Therefore, research in this area is necessary since limited consensus having been reached with regard
to the basic essential components of this rehabilitation.
Consensus has, however, been reached on the use of decongestive lymphedema therapy (DLT), but due to a lack
of tests, the necessary dosages are unknown and its level is moderately strong.
This study attempts to verify both the efficacy of activity-oriented proprioceptive antiedema therapy (TAPA), as
compared to conventional treatments such as DLT or Complex Physical Therapy (CPT), as well as its efficiency in
terms of cost-effectiveness, for patients affected by breast cancer-related arm lymphedema.
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Methods: Controlled, randomized clinical trial with dual stratification, two parallel arms, longitudinal and single
blind. 64 women with breast cancer-related arm lymphedema will take part in the study. The experimental group
intervention will be the same for stage I and II, and will consist of neuro-dynamic exercises oriented to the activity,
proprioceptive neuromuscular facilitation activities and proprioceptive anti-edema bandaging. The control group
intervention, depending on the stage, will consist of preventive measures, skin care and exercise-prescribed training
in the lymphedema workshop as well as compression garments (Stage I) or conservative Complex Decongestive
Therapy treatment (skin care, multi-layer bandaging, manual lymphatic drainage and massage therapy) (Stage II).
Results: Sociodemographic and clinical variables will be collected for the measurement of edema volume and ADL
performance. Statistical analysis will be performed on intent to treat.
Discussion: It has been recommended that patient training be added to DLT, as well as a re-designing of patient
lifestyles and the promotion of health-related aspects. In addition, clinical trials should be undertaken to assess
neural mobilization techniques and proprioceptive neuromuscular facilitation should be included in the therapy.
Cohesive bandaging will also be performed as an early form of pressotherapy. The proposed study combines all of
these aspects in order to increased comfort and promote the participation of individuals with lymphedema in
everyday situations.
Limitations: The authors have proposed the assessment of the experimental treatment for stages I and II. One
possible limitation is the lack of awareness of whether or not this treatment would be effective for other stages as
well as the concern for proper hand cleansing during use of bandages, given the current COVID-19 pandemic situation.
Trial registration: This trial was registered in ClinicalTrials.gov (NCT03762044). Date of registration: 23 November 2018.
Prospectively Registered.
Keywords: Occupational therapy (OT), Breast cancer (BC) - lymphedema (L), Activity-oriented proprioceptive antiedema
therapy (TAPA in Spanish), Health-related quality of life (HRQOL), Complex decongestive therapy (CDT)
Background
Breast cancer (BC) is a major public health issue, being
the most common global cause of cancer-related deaths
in females and the second most common form of cancer,
with over 2 million new cases occurring in 2018 [1]. BC
survival rates have improved notably over the past 20
years (survival from this type of tumor increases by 1.4%
annually) [2]. BC survivors face challenges in their activ-
ities of daily living (ADL), as a result of both the illness
and the subsequent treatments undertaken. These chal-
lenges include altered sensory and pain functions and
neuromusculoskeletal and movement-related alterations,
as well as alterations of the skin and related structures.
These symptoms tend to continue for extended periods
of time and therefore, BC survival has been categorized
as a chronic illness with new challenges arising for re-
habilitation services [3, 4].
It is estimated that more than one out of every five
women treated for BC will develop lymphedema in an
upper extremity (20% in 6 months, 36% in 1 year and
54% within 36months). The most relevant risk factors
are the number of lymph nodes excised in surgery, radi-
ation therapy and obesity. This is a chronic and progres-
sive disorder that causes edema, skin changes (which
may cause fibrosis and deformity), pain, sensitivity alter-
ations, fatigue, limitations in joint rotation, recurrent in-
fections, an inability to independently carry out ADL,
low self-esteem, etc. Although it has been recognized for
years now, consensual treatment dose programs have yet
to be established [5].
Tertiary prevention in BC attempts to combat the con-
sequences of this illness. It includes aspects such as re-
habilitation, relapse prevention, early diagnosis of second
malignancies, management of late complications through
treatments and emotional support. This type of assist-
ance has been traditionally presented for some time now
in specialized health care, but it is currently becoming
an increasing primary care responsibility [6, 7].
Rehabilitation of BC patients is intended to ensure
their social integration and participation. Current evi-
dence suggests the importance of transdisciplinary onco-
logical rehabilitation. Therefore, research in this area is
essential [8], since it is of great importance and quite dif-
ferent from the treatment phase and should include
physical and occupational therapies (OT) [9]. Numerous
rehabilitation models currently exist, but consensus has
not been reached as to the basic necessary components
of integral rehabilitation for cancer survivors [10, 11].
The regional government of Andalusia (Spain) designed
an Integrated Palliative Care Process (IPC) for BC [12],
which includes aspects to be carried out during the re-
habilitation process, including lymphedema therapy,
whose implementation has been quite disparate in the
distinct provinces of the region. The literature also finds
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follow up recommendations based on risk factors and
care level [7].
Consensus has been reached with regard to the utility
of decongestive lymphedema therapy [13] but tests have
yet to determine the optimal treatment dosage to be
used and the level of evidence regarding its effectiveness
in lymphedema treatment is only moderately strong, due
to a limited number of randomized trials conducted with
control groups, a lack of well-controlled interventions
and measurements of precise volume, mobility or func-
tion and quality of life [5, 14, 15]. Similarly, the prescrip-
tion of compression garments for lymphedema is quite
varied and may be due to the lack of underlying evi-
dence to inform on the treatment [16–18].
Evidence also suggests that complete and effective
post-operative BC rehabilitation should also include
patient self-control (empowerment), focus on the rede-
signing of their life style and include health promotion
aspects [8, 19–21].
Studies have also confirmed that women with lymph-
edema and pain following BC may present alterations in
their neuro-mechanical sensitivity [22] and neuropathic
pain, as a result of nerve compression, or peripheral
neuropathy induced by chemotherapy [2]. So, clinical tri-
als should be carried out to assess neural mobilization
techniques that focus on the functionality of the upper
limbs [23], based on the clinical neural mobilization
mechanism to reduce the intra-neural edema [24].
Studies have suggested the incorporation of propriocep-
tive neuromuscular facilitation elements (PNF) with trad-
itional methods of manual lymphatic drainage (MLD), to
facilitate the treatment process for lymphedema patients,
since they induce powerful synergic effects on edema vol-
ume, range of motion (ROM) of the shoulder, pain and
depression [25]. Their independent or combination use
with laser treatment has also been suggested, since im-
provements were also found in these variables and even in
the rate of blood circulation in the underarm [26]. Also, in
a study in which bandaging was not used, CDT was com-
bined with PNF and respiration, reducing the lymph-
edema and also improving ROM [27], which could
potentially improve activity performance, participation
level and thus, quality of life [14, 28].
In response to the evidence regarding the use of the
Coban®3M bandage as an early precursor to pressother-
apy in the rehabilitating treatment of lymphedema to
reduce prolonged edema (the causal agent of multiple
complications and functional loss) [18, 29–31], we
propose the possibility of testing the effectiveness of
similar bandages, but ones that avoid compressive
syndromes, decrease pain and edema, promote the de-
velopment of ADL and improve the treatment’s cost-
effectiveness [32, 33]. We suggest combining its use with
the three previously mentioned techniques (healthcare
education/patient training, neuro-dynamic activities
geared to neuro-muscular use and proprioceptive neuro-
muscular facilitation oriented towards ADL) and which,
collectively, are referred to as “TAPA” (in Spanish,
Activity-oriented proprioceptive antiedema therapy).
Given the consensus for conservative lymphedema
treatment, such as Complex Decongestive Therapy (CDT)
or Complex Physical Therapy (CPT), we believe that com-
parison with our TAPA treatment should be made with
this type of treatment.
This study attempts to assess the effectiveness of
TAPA, in terms of cost-effectiveness, calculating costs of
material and human resources. Current expenditure on
bandaging materials for CDT is at least double that
which would be spent on TAPA, since, instead of multi-
layers (usually two or three) only one is used here, and
patients may require an annual prescription for com-
pression garments, included in the catalogue of ortho-
prosthetic products of the Andalusian Health Service
[34] and the use of these is minimized by TAPA.
Personnel expenses for CDT are for approximately 60
min per treatment, using an individual approach for-
mula, while TAPA sessions are approximately 30 min,
and are carried out individually, with the possibility of a
group approach. This, as well as the effectiveness of the
treatment in terms of measurement of the reduced vol-
ume of the lymphedema, will improve the functionality
of the upper extremity, during the performance of daily
living activities (occupational) and therefore, in HRQOL.
Hypotheses and objectives
Hypothesis: Activity-oriented proprioceptive antiedema
therapy is more cost-effective than standard treatment.
Objectives
This study aims to verify both the efficacy of the new
therapy (TAPA) versus conventional treatment, as well
as its efficiency in terms of cost-effectiveness, in patients
suffering from Breast Cancer-Related Arm Lymphedema
(BCRAL).
Specific objectives
 To measure the decrease in volume of the affected
limb treated with TAPA and the maintenance of the
effect over time (1 month and 3 months).
 To evaluate its effect on the performance of
activities of daily living (ADL).
 To evaluate its effect on health-related quality of life
(HRQOL).
 To determine efficiency in terms of simplicity of
handling and economy of the anti-edema bandage
technique used in the TAPA group.
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Methods
Design
Controlled clinical trial, randomized by stratification in
two gradients, with two parallel arms, longitudinal and
single blind. To measure the efficiency of the new treat-
ment, a cost-effectiveness study will be performed [34–36]
.
Study subjects
The study population will be females who were treated
for breast cancer, diagnosed with Breast Cancer-Related
Arm Lymphedema (BCRAL), referred to the UGC Re-
habilitation Inter-levels of the Reina Sofía Hospital–Cór-
doba and Guadalquivir health district, from either the
multi-disciplinary breast department of Specialized Care
or the Primary Care teams, whose flow diagram of refer-
rals to rehabilitation, both in-hospital and at home, for
the treatment of post-mastectomy lymphedema and for
individual or group treatment, is described in the Guide




– Women, treated for BC with a diagnosis of level I
and II BCRAL, according to stratification of the
Work Group of the 11th International Congress of
Lymphology [38], which establishes:
• Stage 1 or mild: difference in the circometry of less
than 4 cm (in volume 10–25%) with respect to the
healthy arm.
• Stage 2 or moderate: difference in the circometry of
between 4 and 6 cm (in volume 25–50%) with respect to
the healthy arm.
– Patient’s informed consent.
Exclusion criteria
– Health problems, illnesses or disabilities that prevent
them from participating in the intervention.
– Other pathologies affecting the HRQOL: untreated
cardiac, renal or respiratory insufficiency.
– Bi-lateral lymphedema.
Participant inclusion
Department specialist in rehabilitation invites the patient
to participate, informing them of the purposes of the re-
search and its procedures.
If they decide to participate, they should sign the In-
formed Consent, which shall be kept by the researcher.
Once the subject is included in the study, they will be
assigned a study protocol number, which will serve to
identify them in all of the study documents. This is a
unique identification number created with an algorithm
based on the center where they came from, their initials
and date of birth, which shall subsequently be encrypted
in an 8-digit number in the coordinating center. The
codes shall be delivered to each researcher at the start of
the study.
Sample size
It is agreed that a decrease in the volume of the clinically
relevant lymphedema may be established at 150 ml.
(minimal detectable value) [39], 20% with respect to the
baseline. Based on data from the literature on means
and standard deviations [25, 40], for an alpha error of
0.05 and a statistical power of 0.80, the necessary sample
size would be 29 subjects per group (calculation per-
formed with EPIDAT 4.2). It is assumed that the stand-
ard treatment effect in the control group will lead to a
reduction in arm volume by an average of 5%, the treat-
ment effect in the experimental group will cause an
average reduction in arm volume of 20%, and the stand-
ard deviation will be similar in both groups, approaching
20% [41]. Taking into account the dropout rate of 10%
in each group, the corrected sample size is 64 patients,
randomly assigned to two groups with 32 patients each.
Randomization
Subjects were selected randomly using stratified random
selection, in stages I or II, according to stratification of
the Work Group of the 11th International Congress of
Lymphology. Following capture and recruitment, partici-
pants were randomly assigned to one of the two groups
(experimental or control).
Random allocation and concealment of allocation
The random assignment sequence was created using
EPIDAT, 3.1 statistical software, which stratifies the pa-
tients according to lymphedema stage, with a 1:1 ratio,
using blocks having a random size of 4. The assignment
sequence was hidden from the researcher assessing the
participants through sequentially numbered envelopes
that are opaque, sealed and stapled.
Allocation will be carried out by a department special-
ist in the Physical Medicine and Rehabilitation
department.
Sampling technique
Consecutive sampling. Patients who comply with the se-
lection criteria will be invited to participate in the study
as they are identified and captured by the field re-
searcher entrusted with this task.
Muñoz-Alcaraz et al. BMC Cancer         (2020) 20:1074 Page 4 of 11
Sampling will be carried out by a department specialist
from the Physical Medicine and Rehabilitation department.
Blinding
Following the assignment of the interventions, these re-
sults will be hidden from the evaluator, who is a final
year medical resident specializing in Physical Medicine
and Rehabilitation (AJ), who will also monitor the data
and data analysts (LA and J), who will not receive infor-
mation on which of the treatments corresponds to the
distinct data.
The party responsible for the random assignment and
participant capture will inform the evaluator and the
participants of the distinct dates of results assessment
for each of them, and they will be reminded of the same
and will have this information confirmed (or modified)
via telephone on the preceding days.
Participants will attach the protocol follow-up sheet,
registering any adverse effects, if occurring, as well as
drop outs, losses and causes for the same.
Study revision by part of the research team is ongoing,
through the use of the new technologies and a formal
quarterly meeting.
Study variables and measurement instruments
The study variables are shown in Tables 1, 2, 3.
Information sources
A data collection notebook/form will be created, which
will be accompanied by a procedures manual.
The following instruments will be used for the measure-
ment (Table 2), comparison and treatment of dependent
variables:
Statistical analysis
Analysis is performed for intent to treat. Data lacking
after the basal measurements are replaced using the last
available observation. Quantitative and qualitative vari-
ables will be described as usual (mean, standard devi-
ation; proportions). An analysis of basal comparability of
the sociodemographic and clinical variables (Table 1)
will be carried out between both treatment groups.
Then, a bivariate analysis will be conducted, previously
verifying that the quantitative variables follow a normal
distribution, using the Kolmogorov-Smirnov or Shapiro-
Wilk tests, in which case, a repeated measures ANOVA
is carried out (Mixed Models), to analyze the profile of
patients from the basal measurement (24–72 h before
treatment onset), after completing 10 sessions and one
and 3 months later. If the variables do not follow a nor-
mal distribution, non-parametric tests will be used
(Friedman’s test). In addition, a multivariate analysis will
be performed, as well as a survival analysis, Cox regres-
sion or multiple linear regression, taking into account
the examined sociodemographic and clinical covariables
resulting statistically significant following the bivariate
analysis, for their inclusion in the model or to be con-
trolled for, given their potential confounding effect. The
main dependent variable will be the reduction of volume
of the affected extremity. Statistical analysis will be per-
formed using the Statistical Package for the Social Sci-
ences (SPSS v.17). Statistical significance values will be
those normally used (p < 0.05) and bilateral contrasts
will be carried out. To evaluate effectiveness, a compara-
tive analysis of economic costs of both treatments will
be performed.
Interventions
Following capture and recruitment, participants were
randomly assigned to one of the two groups.
Both groups will receive a 3-h long healthcare educa-
tion workshop on lymphedema (Lymphedema work-
shop), led by a department specialist in the Physical
Medicine and Rehabilitation Dept. of the Clinical Inter-
level Rehabilitation Management Area (MV), and offer-
ing basic knowledge on the physiopathology of lymph-
edema, identification of symptoms, preventive skin care
measures, ADL orientation, including physical activity
and recommendations for neck and arm anti-edema ex-
ercises and postures to be carried out at least once daily.
The interventions used for the Experimental group will
be the same for stage I and II, and will receive 10 ses-
sions (2 per week), of 30 min each, led by an Occupa-
tional Therapist from the Córdoba and Guadalquivir
health district (MN):
− 10-min neuro dynamics oriented to the activity.
− 10-min proprioceptive neuromuscular facilitation
activities.
− 10-min proprioceptive anti-edema bandaging, in-
cluding patient and/or caretaker instructions for place-
ment, as well as assistance on techniques to use for
performing everyday activities.
Proprioceptive anti-edema bandaging will be placed
after carrying out the neuro dynamic and neuromuscular
facilitation activities. Cohesive elastic bandages will be
used, containing a high content of cotton and anti-slip.
The Control group intervention, depending on the
stage, will be led by a physiotherapist from the Reina
Sofía Hospital in Córdoba, and will consist of:
Stage I:
- Preventive measures, skin care and exercise pre-
scribed by the rehabilitation physician and training in
the lymphedema workshop.
- Compression garments.
-Duration of 5 weeks.
Stage II:
Ten sessions of 60 min of conservative treatment of
Complex Decongestive Therapy (the literature does not
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refer to specific protocols to quantify session duration,
therefore, expert opinions based on everyday practice




Table 1 Independent study variables and their measurement instruments
INDEPENDENT VARIABLES
(Sociodemographic and clinical variables)
MEASUREMENT INSTRUMENTS (to be filled in with information from interviews and
clinical records)
- ID: Identification number for the study (1, 2, 3...) ID:
- Age. Date of bird _/_/_
_ years old
- Group (Treatment carried out): TAPA / standard.
- Work activity: Working (Which?)
/Retired/Unemployed/Others (Which?)
- Menstrual situation: Pre-menopausal/Post-menopausal
- Laterality: Right/ left/Both
- Body mass index (BMI):
- Obesity:
BMI: height/weight2
yes (BMI > =30)/ no (BMI < 30)
- AHT (Arterial hypertension): Yes (> = 120/80mmHg/take medication) / no (< 120/80mmHg)
- DLP (Dyslipidemia): Yes (> = 200mg dl/take medication) / no (< 200mg/dl)
- DM (Diabetes): Yes (> = 126mg dl/take medication) / no (< 126mg/dl)
- Heart disease: Yes / no
- Kidney failure: Yes / no Yes / no
- Vascular disease: Yes /no Yes / no
- Thyroid disease: Yes / no Yes / no
- Pacemaker: Yes / no Yes / no
- Electro-stimulator: Yes /no Yes / no
- Date of BC diagnosis _/_/_
- Date of lymphedema diagnosis _/_/_
- Stage: I, II
- Edema location: Hand(H)/Forearm (F)/Arm (A)/ Breast
H + F/ H + F + A/ F + A/ Complete/ Others (this category should be thoroughly considered)
- Breast: Right/ left
- Date of surgical intervention: _/_/_
- Type of tumor:
- Intervention type: Conservative/mastectomy
ductal infiltrating/in situ/ lobular/ inflammatory/tubular/other (which?):
Conservative/mastectomy
- Axillary surgery: sentinel ganglion biopsy (SGB)/ lymphadenectomy /Both/none
- No. of excised ganglia: N°
- No. positive ganglia: N°
- Complications: Infection/ hematoma/ seroma/nerve lesion/Axillary web syndrome
- Chemotherapy: Yes / no
- Radiotherapy: Yes / no
- Hormone therapy: Yes / no
- Immunotherapy: Yes / no
- Breast reconstruction: Yes / no
Yes:
- Type of reconstruction: Prosthesis/back/ abdomen
- Reconstruction time: Immediate/ deferred
- Date of symptom onset: _/_/_
- Lymphedema: Right/ left
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Table 2 Primary dependent study variables and their measurement instruments
PRIMARY DEPENDENT VARIABLES MEASUREMENT INSTRUMENTS/INTERPRETATION OF RESULTS
- Treatment adherence: - yes/no
Calculation of the percentage of treatment compliance for therapeutic adherence.
PC = number of activities performed by patient/number of activities prescribed by
the therapist *100. If PC is equal to or over 80%, it is considered that there was
good treatment adherence. If less, no.
-Physical state of the limb (inspection and palpation of the affected area). Photographs
will be taken of the limb [42].
- Skin hydration:
- Skin lesions:
- Nail lesions: Yes / no
- Induration / Fibrosis: Yes / no
- Pitting edema: Yes / no







-Visual analogue scale (VAS), where 0 is no pain, heaviness or tension and 10 is







- Shoulder joint rotation: Degrees with goniometer:
Flexion___/Abduction___/External rotation___
-Volume, through circometry (manual measurement of perimeters of the limbs with a
tape measure, the value of the volume is approximate and volume is calculated using
the Kuhnke formula Vol = (C1 2 + C2 2 +… Cn 2)/ π)) [43–45].
- Degree of lymphedema (according to %
of volumetric):
_Grade 1 or mild: difference in circometry less than 4 cm (in volume 10–25%) with respect
to the healthy arm.
_Grade 2 or moderate: difference in circometry between 4 and 6 cm (in volume 25–50%)
with respect to the healthy arm.
- Volumetric %:
- Difference in volume in % between both extremities:




*an edema reduction of 150 ml over the basal value is required in order to be considered
clinically relevant
- Function of the upper limb/activity performance. - Value of Quick Disabilities of the Arm, Shoulder and Hand (Quick DASH) [21], with
transcultural, reliability, validity and sensitivity adaptation to changes of its extended
version in 2006 [46, 47].
- Quick DASH value = __% (the result is calculated as a percentage, the higher the obtained
result, the greater the disability or symptom)
- Treatment costs Sum of expenses:
-Prescription of compression garment:
Yes (specify type and cost ______________) / NO
- Type of bandaging used:
proprioceptive / multi-layer (number of rolls used per price of each of the same)
- Total number of treatment hours with therapist:
5/10/other (which:___) (number of hours used per professional hour price)
Table 3 Study secondary dependent variable and its measurement instruments
SECONDARY DEPENDENT VARIABLE MEASUREMENT INSTRUMENTS/INTERPRETATION OF RESULTS
-Health related quality of life (HRQOL). - Value of Upper Limb Lymphedema 27 (ULL-27), specific instrument for patients with Breast
Cancer-Related Arm Lymphedema, transculturally adapted and validated in its Spanish version
in 2016 [48]. (The result is calculated as a percentage of social, physical and psychological
dimensions in which the higher the result obtained, the greater the disability or symptom/poorer
the HRQOL).
- Health Questionnaire EQ-5D-5L by EuroQol Group, generic and standardized instrument
used to describe and value the HRQOL of a group or population and validated in Spain by
Badia X. et al. in 1999 [49]. Numeric value between 3 and 45, in which the higher the score,
the poorer the HRQOL.
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-Massage therapy (22).
Participants will be notified that during the interven-
tion and follow-up period, they may not undertake other
treatment for their BCRAL and, in the case of being sub-
ject to experimental treatment and not achieving the ex-
pected edema reduction, they may complete standard
treatment upon study completion.
To analyze the patient profile from the basal measure-
ment (24–72 h prior to treatment onset), until immediately
following completion of the 10 sessions and one and 3
months later (Fig. 1).
Study duration
The anticipated study duration is 18 months, which may
be modified based on the patient recruitment period. In
Fig. 2, Gantt’s study diagram is shown.
Fig. 1 Study flow design
Muñoz-Alcaraz et al. BMC Cancer         (2020) 20:1074 Page 8 of 11
Expected results
For the desirable data following data analysis, the experi-
mental treatment would include the following:
– Reduce the volume of the affected extremity by at
least 150 ml. more than the control group
intervention.
– Positively impact the treated patient’s HRQOL,
improving the mean scores of the three dimensions
from the ULL-27 questionnaire by at least 12.58
points (minimum detectable change).
– Improve the functionality of the upper limbs
affected by lymphedema, measured using Quick
Dash on at least 15 points.
– Reduce costs by at least 50% with respect to
standard treatments in the respective stage.
Discussion
The experimental TAPA treatment attempts to incorp-
orate the advantages of comfort with respect to standard
treatment by substituting compressive elements for pro-
prioceptive ones, which facilitate the participation of the
individuals suffering from the lymphedema in everyday
situations.
It is conceptualized as a patient-focused, personalized
treatment, in which the significant prescribed activities
adapt to each case.
Based on the study’s anticipated results, TAPA may re-
sult in the creation of the first lymphedema rehabilita-
tion protocol in an upper limb, secondary to breast
cancer, which reduces intervention costs.
The recommended occupational therapy contribution
based on evidence from lymphedema rehabilitation, sug-
gests the inclusion of the occupational needs of the
attended individuals and the adaptation to their everyday
surroundings, potentially improving their self-perception
of the health-related quality of life.
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